Headlines
-
FIP seeks robust regulations
Wednesday | Sep 4 2024THE International Pharmaceutical Federation (FIP) has called for pharmacies to be defined as healthcare facilities and for pharmacists to be recognised as healthcare providers, in order to achieve a fully profession-centred, service-oriented practice model.
-
PSA CEO calls to cut carbon footprint
Tuesday | Sep 3 2024STEVE Morris, CEO of the Pharmaceutical Society of Australia (PSA), is calling on pharmacists to play a crucial role in addressing healthcare's environmental impact.
-
Wizard Pharmacy opens new WA store
Tuesday | Sep 3 2024WIZARD Pharmacy Albany Hacienda officially opened last week, with Member for Albany, Rebecca Stephens, leading the grand opening.
-
Teaching to breathe easier
Tuesday | Sep 3 2024WITH Asthma Week currently underway, regional pharmacists are invited to take part in a cross-disciplinary asthma and hayfever awareness seminar, conducted by part-time pharmacist Sherri Barden from Moama Village Pharmacy.
-
IPA unveils strategy, honours suppliers
Monday | Sep 2 2024THE Independent Pharmacies of Australia Group (IPA) revealed strategic plans for 2025 at its Impact Partnership Forum and held its awards gala in Melbourne last week.
-
Tas vape sale restrictions
Monday | Sep 2 2024THE Tasmanian Government announced on Fri new tighter regulations restricting the sale of nicotine-containing vapes to patients with a prescription from a GP or nurse practitioner.
-
MedAdvisor aces FY24
Friday | Aug 30 2024STRONG growth in Australia has helped MedAdvisor Solutions achieve robust results for FY24, with a revenue increase of 24.6% on the previous corresponding period to $122.1 million.
-
Enhertu gets PBS listing
Friday | Aug 30 2024AUSTRALIANS with a newly defined type of metastatic breast cancer, HER2-low, will now have access to a life-prolonging drug under the PBS from 01 Sep.
-
Mixed results at Priceline
Thursday | Aug 29 2024WESFARMERS has today reported strong growth in revenue across its Health division and its Australian Pharmaceutical Industries (API) subsidiary, despite a significant reduction in COVID-19 anti-viral product sales.
-
Approval for Sandoz’s drugs
Thursday | Aug 29 2024SANDOZ ANZ has received regulatory approval for two denosumab biosimilars, Jubbonti, for treating osteoporosis in post-menopausal women and, Wyost, for cancer-related bone disease.
